Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer
This study is currently recruiting patients.
Sponsored by: | European Organization for Research and Treatment of Cancer |
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy, such as mitomycin, fluorouracil, and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known whether radiation therapy and mitomycin are more effective when combined with fluorouracil or with cisplatin in treating anal cancer .
PURPOSE: Randomized phase II/III trial to compare the effectiveness of radiation therapy and mitomycin combined with either fluorouracil or cisplatin in treating patients who have locally advanced anal cancer.
Condition | Treatment or Intervention | Phase |
---|---|---|
squamous cell carcinoma of the anus stage II anal cancer stage IIIA anal cancer stage IIIB anal cancer |
Drug: cisplatin Drug: fluorouracil Drug: mitomycin Procedure: chemotherapy Procedure: radiation therapy |
Phase II Phase III |
MedlinePlus related topics: Anal Cancer; Cancer; Colonic Diseases; Colorectal Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II/III Randomized Study of Radiotherapy With Mitomycin and Fluorouracil Versus Mitomycin and Cisplatin in Patients With Locally Advanced Anal Cancer
OBJECTIVES: Phase II
Phase III
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, T stage (T2 vs T3 vs T4), and nodal status (N0 vs N+). Patients are randomized to 1 of 2 treatment arms.
Quality of life is assessed at baseline, at weeks 12 and 26, and then every 6 months for 2 years.
Patients are followed every 2 weeks for 8 weeks, at week 26, and then every 6 months thereafter.
PROJECTED ACCRUAL: A total of 678 patients (80 [40 per treatment arm] for phase II and 598 [299 per treatment arm] for phase III) will be accrued for this study within 2-5 years.
Eligibility
Ages Eligible for Study: 18 Years - 75 Years, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Location and Contact Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |